April 4, 2016 | Israel’s BiondVax Pharmaceuticals announced today that recruitment of all 224 participants in a Phase 2b clinical trial of M-001, its universal flu vaccine candidate, is complete. The trial, conducted in collaboration with the EU-sponsored UNISEC consortium, is designed to evaluate the safety and immunogenicity of M-001 when used ahead of an avian influenza vaccine. According to the company, this milestone brings their multi-strain and multi-season vaccine against seasonal and pandemic flu one step closer to market. Results from this trial are expected late 2016 or early 2017. BiondVax was founded in 2003 and is headquartered in Nes Ziona.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024

TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024

Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024

BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments